# Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan

> **NCT03324542** · — · COMPLETED · sponsor: **Changhua Christian Hospital** · enrollment: 63 (actual)

## Conditions studied

- AMD

## Interventions

- **DRUG:** Aflibercept [Eylea]

## Key facts

- **NCT ID:** NCT03324542
- **Lead sponsor:** Changhua Christian Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-03
- **Primary completion:** 2017-10-13
- **Final completion:** 2017-10-15
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324542, "Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03324542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*